Objective: To assess the efficacy of orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC) and the impact of current staging criteria on long term survival.
Summary Background Data: HCC is becoming an increasingly common indication for OLT. Medicare approves OLT only for HCCs meeting the Milan criteria, thus limiting OLT for an expanding pool of potential liver recipients. We analyzed our experience with OLT for HCC to determine if expansion of criteria for OLT for HCC is warranted.
Methods: : All patients undergoing OLT for HCC from 1984 to 2006 were evaluated. Outcomes were compared for patients who met Milan criteria (single tumor < opr =5 cm, maximum of 3 total tumors with none >3 cm), University of California, San Francisco (UCSF) criteria (single tumor <6.5 cm, maximum of 3 total tumors with none >4.5 cm, and cumulative tumor size <8 cm), or exceeded UCSF criteria.
Results: A total of 467 transplants were performed for HCC. At mean follow up of 6.6 +/- 0.9 years, recurrence rate was 21.2%, and overall 1, 3, and 5-year survival was 82%, 65%, and 52%, respectively. Patients meeting Milan criteria had similar 5-year post-transplant survival to patients meeting UCSF criteria by preoperative imaging (79% vs. 64%; P = 0.061) and explant pathology (86% vs. 71%; P = 0.057). Survival for patients with tumors beyond UCSF criteria was significantly lower and was below 50% at 5 years. Multivariate analysis showed that tumor number (P < 0.001), lymphovascular invasion (P < 0.001), and poor differentiation (P = 0.002) independently predicted poor survival.
Conclusions: This largest single institution experience with OLT for HCC demonstrates prolonged survival after liver transplantation for tumors beyond Milan criteria but within UCSF criteria, both when classified by preoperative imaging and by explant pathology. Measured expansion of OLT criteria is justified for tumors not exceeding the UCSF criteria.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1959350 | PMC |
| http://dx.doi.org/10.1097/SLA.0b013e318148c704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pre-transplant Loco-Regional Therapy for Hepatocellular Carcinoma and Post-transplant Outcomes: A National Study.
Cureus
August 2024
Center for Abdominal Transplantation, Saint Louis University School of Medicine, Saint Louis, USA.
The ultimate preferred treatment for hepatocellular carcinoma (HCC) complicated with cirrhosis and portal hypertension is an orthotopic liver transplant (OLT). Loco regional therapy (LRT) has emerged to prevent tumor growth and progression of disease beyond the Milan criteria to achieve transplant. There is a paucity of data regarding safety, posttransplant survival benefits, and tumor recurrence rate achieved by these LRT modalities.
View Article and Find Full Text PDFRemote Hepatocellular Carcinoma Recurrence to Lumbar Spine Post Orthotopic Liver Transplantation-A Report of Two Cases and a Review of the Literature.
Transplant Proc
September 2024
Department of Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California; Department of Transplant Hepatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
Late recurrence of hepatocellular carcinoma (HCC) following orthotopic liver transplant (OLT) is infrequently reported, and among cases, those isolated to the spine are rare. Prognoses are poor for this patient population, and no work has been undertaken to create uniform guidelines for management. Here, we report two cases of late recurrent HCC to the spine after OLT and favorable survival outcomes following intervention.
View Article and Find Full Text PDFHepatic Resection as the Primary Treatment Method for Hepatocellular Carcinoma After Orthotopic Liver Transplantation.
Ann Surg Oncol
December 2024
Emory University, Atlanta, GA, USA.
Article Synopsis
- Liver transplantation is the main treatment for severe liver diseases and certain cancers, but there is limited information on managing tumors that appear after the transplant.
- A study of 54 patients who underwent liver surgery after transplantation found that most had hepatocellular carcinoma (HCC) and many did not receive additional therapies before or after surgery.
- The results indicate that liver resection is generally safe after transplantation, with survival rates comparable to those in patients without a transplant, and should be considered for well-selected patients.
Salvage radiofrequency ablation for microwave ablation treated hepatocellular carcinoma complicated by gas gangrene: case report.
J Ultrasound
September 2024
Malattie Apparato Digerente, ASL Salerno, Ospedale L. Curto, Polla, Italy.
Article Synopsis
- Gas gangrene (GG) is a rare but severe infection often caused by Clostridium species, commonly developing after surgeries.
- A case study describes a 76-year-old woman who developed GG in the liver after a microwave (MW) ablation for liver cancer, initially misdiagnosed as an anaerobic liver abscess.
- The successful treatment involved percutaneous Radiofrequency ablation (RFA) when antibiotics failed, suggesting RFA as a potential option for GG when surgery isn't feasible.
Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma.
J Clin Med
May 2024
Sherrie and Alan Conover Center for Liver Disease and Transplantation, JC Walter Jr. Center for Transplantation, Houston Methodist Hospital, Houston, TX 77030, USA.
Hepatocellular carcinoma (HCC) is widely recognized as the predominant type of primary liver malignancy. Orthotopic liver transplantation (OLT) has emerged as a highly effective treatment option for unresectable HCC. Immunotherapies as neoadjuvant options are now being actively investigated in the transplant oncology era to enhance outcomes in patients with HCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!